This Week’s Biopharma News: Amgen Deepens US Manufacturing Push
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
False
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
August 24, 2026
5 min read
A new preservation method could remove a major barrier to treatment, the FDA approves the first gene therapy for GSDIa, and ultrasound directs CAR T cells toward solid tumors
August 18, 2026
10 min read
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
August 17, 2026
5 min read
Biopharma labs are investing heavily in digital tools, but without trusted data architecture, each new platform can add another point of failure
August 17, 2026
3 min read
PRAME-targeted T cells produce a complete response in metastatic nephroblastoma, CAR T cells remain active after a decade, and an in vivo CRISPR screen identifies edits that strengthen solid-tumor activity
False
Affiliations:
Specialties:
Areas of Expertise: